Details for New Drug Application (NDA): 089520
✉ Email this page to a colleague
NDA 089520 describes PROCAINAMIDE HYDROCHLORIDE, which is a drug marketed by Ani Pharms, Ascot, Ivax Sub Teva Pharms, Lannett, Lederle, Roxane, Vangard, Watson Labs, Abraxis Pharm, Gland Pharma Ltd, Hikma, Hospira, Intl Medication, Nexus, Pharmafair, Smith And Nephew, Solopak, Warner Chilcott, West-ward Pharms Int, Inwood Labs, and Sandoz, and is included in fifty-nine NDAs. It is available from seven suppliers. Additional details are available on the PROCAINAMIDE HYDROCHLORIDE profile page.
The generic ingredient in PROCAINAMIDE HYDROCHLORIDE is procainamide hydrochloride. There are nine drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the procainamide hydrochloride profile page.
The generic ingredient in PROCAINAMIDE HYDROCHLORIDE is procainamide hydrochloride. There are nine drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the procainamide hydrochloride profile page.
Summary for 089520
| Tradename: | PROCAINAMIDE HYDROCHLORIDE |
| Applicant: | Watson Labs |
| Ingredient: | procainamide hydrochloride |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 089520
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 1GM | ||||
| Approval Date: | Jan 15, 1987 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
